A Study on the Pharmacokinetic Interactions of Cannabidiol, Amitriptyline, and Tramadol in Neurological Assessments

The primary objective of the study titled "CBD, amitriptyline and tramadol drug-drug interaction study" is to evaluate the **neurological assessments** associated with the concurrent use of cannabidiol (CBD), amitriptyline, and tramadol. This investigation is clinically relevant as it aims to understand the potential interactions between these compounds, which are commonly used in the management of various neurological conditions. Understanding these interactions is crucial for optimizing therapeutic strategies and ensuring patient safety.

The clinical trial involves a study population that includes both **male** and **female** participants. The age range of the participants is categorized as adults, specifically those aged 18 to 64 years. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants are expected to undergo **neurological assessments** as part of the trial. The selection process for the trial population, as well as any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Additionally, the sponsor has not provided key inclusion or exclusion criteria for the study.

The clinical trial is designed to evaluate the **drug-drug interaction** between CBD, amitriptyline, and tramadol, focusing on **neurological assessments**. This study is a Phase 4 trial, indicating it is conducted after the drugs have been approved for public use, to gather additional information on their effects in a larger population. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected. The estimated recruitment start date is December 11, 2023, with an anticipated end date of February 3, 2024, making the overall trial duration approximately two months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve comprehensive assessments to ensure participants meet the necessary conditions for inclusion. Following the screening, participants will be randomly assigned to receive either the study drugs or a placebo, with neither the participants nor the researchers knowing which treatment is being administered, thus maintaining the double-blind nature of the trial. Throughout the study, there will be scheduled follow-up visits to monitor the participants' health, assess the effects of the drug interactions, and ensure adherence to the study protocol. These visits are crucial for collecting data on the primary and secondary endpoints of the trial.

The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall impact of the drug interactions. The expected length of participant involvement is approximately two months, aligning with the trial's overall duration. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with the study protocol, or withdraw consent. The trial is structured to ensure the safety and well-being of all participants while providing valuable insights into the interactions between the study drugs.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not present in the provided data. As such, these aspects cannot be detailed in the description.

The clinical trial is in Phase 4, with an estimated recruitment start date of December 11, 2023, and an estimated end date of February 3, 2024. Efficacy will be assessed through the evaluation of primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will likely involve the collection and analysis of data at various timepoints throughout the study duration. The methods and tools for measuring efficacy parameters are not specified in the available information. The trial is categorized under trial category 1, with a trial category ID of 21988.